300122 智飞生物
已收盘 06-12 15:00:00
资讯
新帖
简况
智飞生物：截至2026年5月29日，公司普通股股东人数为115,077
证券之星 · 06-05
智飞生物：截至2026年5月29日，公司普通股股东人数为115,077
智飞生物：2025年度研发投入达14.36亿元
证券之星 · 06-05
智飞生物：2025年度研发投入达14.36亿元
智飞生物：公司自去年以来采取一系列措施促进公司生产经营稳健发展
证券之星 · 06-05
智飞生物：公司自去年以来采取一系列措施促进公司生产经营稳健发展
智飞生物：防未病治已病，守护人类健康
证券之星 · 06-05
智飞生物：防未病治已病，守护人类健康
智飞生物：公司利拉鲁肽注射液、德谷胰岛素注射液两款产品处于上市审评阶段
证券之星 · 06-05
智飞生物：公司利拉鲁肽注射液、德谷胰岛素注射液两款产品处于上市审评阶段
智飞生物：公司以“技术&市场”双轮驱动发展
证券之星 · 06-05
智飞生物：公司以“技术&市场”双轮驱动发展
智飞生物（300122）披露2025年年度股东会决议公告，6月2日股价下跌2.7%
证券之星 · 06-02
智飞生物（300122）披露2025年年度股东会决议公告，6月2日股价下跌2.7%
股市必读：智飞生物（300122）5月29日董秘有最新回复
证券之星 · 06-01
股市必读：智飞生物（300122）5月29日董秘有最新回复
智飞生物：15价肺炎结合疫苗目前处于上市审评阶段
证券之星 · 05-29
智飞生物：15价肺炎结合疫苗目前处于上市审评阶段
智飞生物：公司员工持股计划正常存续中
证券之星 · 05-29
智飞生物：公司员工持股计划正常存续中
智飞生物：公司以“技术&市场”双轮驱动发展
证券之星 · 05-29
智飞生物：公司以“技术&市场”双轮驱动发展
智飞生物：公司研发、生产、销售等工作持续开展中
证券之星 · 05-29
智飞生物：公司研发、生产、销售等工作持续开展中
智飞生物：司美格鲁肽注射液（超重/肥胖）正处于Ⅲ期临床试验阶段
证券之星 · 05-22
智飞生物：司美格鲁肽注射液（超重/肥胖）正处于Ⅲ期临床试验阶段
智飞生物：人二倍体狂犬病疫苗等五款核心产品已提交上市申请
证券之星 · 05-22
智飞生物：人二倍体狂犬病疫苗等五款核心产品已提交上市申请
智飞生物：持续加快产品创新，推动在研管线进展
证券之星 · 05-22
智飞生物：持续加快产品创新，推动在研管线进展
股市必读：智飞生物（300122）5月15日董秘有最新回复
证券之星 · 05-18
股市必读：智飞生物（300122）5月15日董秘有最新回复
智飞生物：公司持续加快产品创新，推动在研管线进展
证券之星 · 05-15
智飞生物：公司持续加快产品创新，推动在研管线进展
智飞生物及董事长蒋仁生收监管函 多期财报数据不准确
中金财经 · 05-11
智飞生物及董事长蒋仁生收监管函 多期财报数据不准确
股市必读：智飞生物（300122）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：智飞生物（300122）5月8日董秘有最新回复
投资“100万只剩几万块”！智飞生物业绩会上遭吐槽，公司去年巨亏147亿，年报开篇向投资人致歉
澎湃新闻 · 05-10
投资“100万只剩几万块”！智飞生物业绩会上遭吐槽，公司去年巨亏147亿，年报开篇向投资人致歉
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":12.36,"timestamp":1781247816000,"preClose":12.36,"halted":0,"volume":27367232,"delay":0,"changeRate":0,"floatShares":1414000000,"shares":2394000000,"eps":-6.1778,"marketStatus":"已收盘","change":0,"latestTime":"06-12 15:00:00","open":12.36,"high":12.47,"low":12.16,"amount":337000000,"amplitude":0.0251,"askPrice":12.37,"askSize":255,"bidPrice":12.36,"bidSize":280,"shortable":0,"etf":0,"ttmEps":-6.1778,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":12.36,"symbolType":"stock","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":13.6,"lowLimit":11.12,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":1.91,"roa":"--","roe":"--","epsLYR":-6.1506,"committee":0.532669,"marketValue":29587000000,"turnoverRate":0.0194,"status":2,"floatMarketCap":17481000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2641116768","title":"智飞生物：截至2026年5月29日，公司普通股股东人数为115,077","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641116768?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:03","pubTimestamp":1780650187,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：截至5月30日，股东总人数是多少？智飞生物回复：您好，截至2026年5月29日，公司普通股股东人数为115,077，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0077","BK0188","LU2580892789.USD","LU1064130708.USD","LU2148510915.USD","BK0196","BK0046","LU1328615791.USD","LU1064131003.USD","LU2580892862.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116782","title":"智飞生物：2025年度研发投入达14.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116782","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641116782?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:01","pubTimestamp":1780650082,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物06月05日在投资者关系平台上答复投资者关心的问题。公司目前的经营状况，是否还能应对在此期间出现的任何突发情况？智飞生物回复：您好，公司持续开展创新研发，2025年度研发投入达14.36亿元，确保在研管线高效推进。目前，公司在研管线共41项产品，其中五款产品已提交上市申请，十余款产品正同步开展临床研究。公司稳步推进自主产品研发上市，持续控制经营风险，促进公司实现可持续发展，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300122","BK0046","BK0188","LU2148510915.USD","LU2580892789.USD","BK0239","LU1064130708.USD","LU1328615791.USD","BK0196","LU2580892862.HKD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143116","title":"智飞生物：公司自去年以来采取一系列措施促进公司生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641143116?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:51","pubTimestamp":1780649471,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：根据公司发布的公告，公司2025年一季报亏损3.05亿元，到了2025年底，全年亏损超147亿元。从这个数据可以看出，公司季度亏损明显加大。公司2026年的经营业绩请您持续关注公司的信息披露，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","BK0239","BK0188","300122","LU2148510915.USD","LU1328615791.USD","LU2580892789.USD","BK0077","BK0046","LU1064131003.USD","LU1064130708.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161181","title":"智飞生物：防未病治已病，守护人类健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641161181?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:51","pubTimestamp":1780649465,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司今后是想发展成为民族医药企业巨头（像默沙东，礼来，诺和诺德），去逐渐占领全球医药市场。还是希望成为外资入股的中外合资医药企业？请详细回答智飞生物回复：您好，公司秉持“防未病治已病，守护人类健康”的使命，创新研发，深耕市场，加速推动优质产品惠及民众。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0188","LU1328615791.USD","BK0077","LU2580892789.USD","LU2148510915.USD","BK0239","BK0196","LU2580892862.HKD","LU1064130708.USD","300122","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641611663","title":"智飞生物：公司利拉鲁肽注射液、德谷胰岛素注射液两款产品处于上市审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2641611663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641611663?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:48","pubTimestamp":1780649295,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物06月05日在投资者关系平台上答复投资者关心的问题。公司利拉鲁肽注射液、德谷胰岛素注射液两款产品处于上市审评阶段，司美格鲁肽注射液（降糖）已完成Ⅲ期临床试验，司美格鲁肽注射液（减重）正处于Ⅲ期临床试验阶段，公司持续推进相关工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2148510915.USD","LU2580892789.USD","LU1064131003.USD","BK0077","300122","BK0196","BK0188","BK0046","LU1064130708.USD","LU1328615791.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641165851","title":"智飞生物：公司以“技术&市场”双轮驱动发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2641165851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641165851?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:42","pubTimestamp":1780648934,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，股价越跌，消费者越恐惧，产品越滞销，这是否是一个恶性循环？如果不是，请用详细销售数据分析回答，谢谢智飞生物回复：您好，公司以“技术&市场”双轮驱动发展，加速推进自研产品上市，目前已有五个产品处于上市审评阶段；优化市场推广策略，强化市场宣传推广，逐步实现公司经营面企稳向好。公司的经营业绩请持续关注公司披露的定期报告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","LU2580892789.USD","BK0239","BK0077","LU1064131003.USD","300122","BK0046","LU2580892862.HKD","LU1064130708.USD","LU1328615791.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640865911","title":"智飞生物（300122）披露2025年年度股东会决议公告，6月2日股价下跌2.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640865911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640865911?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:43","pubTimestamp":1780393389,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，智飞生物报收于13.33元，较前一交易日下跌2.7%，最新总市值为319.09亿元。该股当日开盘13.7元，最高13.71元，最低13.29元，成交额达2.03亿元，换手率为1.07%。近日，重庆智飞生物制品股份有限公司披露《2025年年度股东会决议公告》。公告显示，公司于2026年6月1日召开2025年年度股东会，会议由董事长蒋仁生主持，采用现场与网络投票结合方式召开。出席会议股东共854人，代表股份1,408,540,200股，占公司有表决权股份总数的58.8414%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","300122","BK0046","LU1064130708.USD","LU2148510915.USD","LU2580892789.USD","BK0077","LU1064131003.USD","LU2580892862.HKD","BK0239","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640598513","title":"股市必读：智飞生物（300122）5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640598513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640598513?lang=zh_cn&edition=full","pubTime":"2026-06-01 03:39","pubTimestamp":1780256350,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，智飞生物报收于13.59元，下跌0.88%，换手率1.53%，成交量21.58万手，成交额2.98亿元。董秘最新回复投资者： 请问董秘，员工持股现在亏损比例是多少？请详细回答董秘： 您好，根据相关规定，公司员工持股计划由其管理委员会负责日常管理事宜，目前该计划正常存续中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","LU1328615791.USD","LU2148510915.USD","BK0239","BK0196","LU2580892862.HKD","LU1064131003.USD","LU2580892789.USD","LU1064130708.USD","BK0077","300122","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639731596","title":"智飞生物：15价肺炎结合疫苗目前处于上市审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2639731596","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639731596?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:18","pubTimestamp":1780064304,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：1.15价肺炎疫苗获批进展，大约什么时间知道能批下来2.司美格鲁肽临床进展到哪个阶段3.公司目前经营状况智飞生物回复：您好，公司15价肺炎结合疫苗目前处于上市审评阶段，司美格鲁肽（降糖）已经完成Ⅲ期临床试验，司美格鲁肽（减重）正处于Ⅲ期临床试验阶段，相关产品的研发信息请您持续关注公司的信息披露。公司正持续加快产品创新，推动在研管线进展，强化市场推广和宣传，以实现公司稳健发展。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0046","LU2148510915.USD","BK0077","300122","159646","LU1328615791.USD","BK0188","BK0239","LU2580892862.HKD","BK0196","LU1064130708.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639731976","title":"智飞生物：公司员工持股计划正常存续中","url":"https://stock-news.laohu8.com/highlight/detail?id=2639731976","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639731976?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:18","pubTimestamp":1780064303,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，市场传闻员工持股计划所持股份早已协议转让给他人，请详细说明一下当前情况！不要再糊弄投资者了！智飞生物回复：您好，公司员工持股计划正常存续中。公司的相关信息请以公司在指定信息披露媒体发布的公告为准。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","BK0239","BK0188","300122","LU2148510915.USD","LU1328615791.USD","LU2580892789.USD","BK0077","BK0046","LU1064131003.USD","LU1064130708.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639867316","title":"智飞生物：公司以“技术&市场”双轮驱动发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2639867316","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639867316?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:18","pubTimestamp":1780064301,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，蒋总成为东土科技前十大股东之一，有资金去投资其他科技公司，为什么不对自家股票进行增持回购？？蒋总对投资者说的和对公司做的，是否一致？请正面回答，不要敷衍了事智飞生物回复：您好，公司以“技术&市场”双轮驱动发展，加速推进自研产品上市，目前已有五个产品处于上市申报阶段；优化市场推广策略，强化市场宣传推广，逐步实现公司经营面企稳向好。感谢您的关注与建议。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300122","BK0046","BK0188","LU2148510915.USD","LU2580892789.USD","BK0239","LU1064130708.USD","LU1328615791.USD","BK0196","LU2580892862.HKD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639673130","title":"智飞生物：公司研发、生产、销售等工作持续开展中","url":"https://stock-news.laohu8.com/highlight/detail?id=2639673130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639673130?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:15","pubTimestamp":1780064121,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司去年亏损147亿元，是否从去年开始，公司就不能持续生产经营了？智飞生物回复：您好，自去年以来公司采取一系列措施促进公司生产经营稳健发展。公司持续加快产品创新，推动在研管线进展；优化市场策略，强化商业推广；提升治理水平，夯实发展根基。公司研发、生产、销售等工作持续开展中，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU2580892862.HKD","BK0188","300122","BK0239","LU1064130708.USD","BK0196","BK0046","LU1328615791.USD","BK0077","LU2580892789.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637397349","title":"智飞生物：司美格鲁肽注射液（超重/肥胖）正处于Ⅲ期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2637397349","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637397349?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:06","pubTimestamp":1779440777,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司减肥产品还有多久才能上市？智飞生物回复：您好，公司司美格鲁肽注射液（超重/肥胖）正处于Ⅲ期临床试验阶段，CA111注射液正处于I期临床试验阶段。相关产品的研发进展请您持续关注公司的信息披露，谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200031099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0077","BK0239","LU1064130708.USD","LU2148510915.USD","LU2580892862.HKD","LU1328615791.USD","BK0188","300122","LU2580892789.USD","BK0046","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637939786","title":"智飞生物：人二倍体狂犬病疫苗等五款核心产品已提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637939786","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637939786?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:00","pubTimestamp":1779440427,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，高层口口声声说大力研发新产品，公司市值都快跌没了，等新产品三年五载出来，市场还会给公司机会吗？你们为什么不快速并购更多公司，增加提升公司价值呢？市场还会给公司时间吗？智飞生物回复：您好，公司目前有五款核心产品已提交上市申请，分别是人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液。公司产品的研发进展请您持续关注公司的信息披露，谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0046","LU2148510915.USD","BK0077","300122","159646","LU1328615791.USD","BK0188","BK0239","LU2580892862.HKD","BK0196","LU1064130708.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637428392","title":"智飞生物：持续加快产品创新，推动在研管线进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637428392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637428392?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:57","pubTimestamp":1779440235,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，创业板指已经创下十几年以来的新高，贵司股价还在不断下跌，公司还有什么实质性的利好，来提升股价，维护投资者信心？？智飞生物回复：您好，公司持续加快产品创新，推动在研管线进展；强化商业推广，优化市场策略；提升治理水平，夯实发展根基，逐步推动公司经营企稳向好，谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0077","BK0239","LU2580892862.HKD","LU1328615791.USD","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","BK0188","LU2580892789.USD","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636101395","title":"股市必读：智飞生物（300122）5月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636101395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636101395?lang=zh_cn&edition=full","pubTime":"2026-05-18 01:48","pubTimestamp":1779040095,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，智飞生物报收于15.04元，下跌0.33%，换手率1.31%，成交量18.54万手，成交额2.79亿元。董秘最新回复投资者： 请问董秘，总裁质押3亿股份资金，是对智飞进行增持，还是收购其他公司？当日关注点来自交易信息汇总：5月15日主力资金净流出2763.43万元，散户资金净流入2773.95万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800000769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","LU2148510915.USD","LU1064130708.USD","LU2580892862.HKD","LU2580892789.USD","BK0077","300122","LU1328615791.USD","BK0239","LU1064131003.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635023267","title":"智飞生物：公司持续加快产品创新，推动在研管线进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2635023267","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635023267?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:45","pubTimestamp":1778834722,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：根据相关财经媒体的报道，公司去年亏损147亿元，居创业板第一。而与亏损相对应的是，公司股价连续下跌了6年，持有公司股票的投资者普遍亏损超50%。请问：公司有无具体扭亏为盈的措施，让股价止跌回稳呢？！智飞生物回复：您好，公司持续加快产品创新，推动在研管线进展；强化商业推广，优化市场策略；提升治理水平，夯实发展根基，逐步推动公司经营企稳向好，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500029431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0077","BK0239","LU1064130708.USD","LU2148510915.USD","LU2580892862.HKD","LU1328615791.USD","BK0188","300122","LU2580892789.USD","BK0046","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634447019","title":"智飞生物及董事长蒋仁生收监管函 多期财报数据不准确","url":"https://stock-news.laohu8.com/highlight/detail?id=2634447019","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634447019?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:29","pubTimestamp":1778480948,"startTime":"0","endTime":"0","summary":"中国经济网北京5月11日讯 深交所网站5月8日发布关于对重庆智飞生物制品股份有限公司及相关当事人的监管函 。 2026年4月28日，智飞生物披露《关于前期会计差错涉及追溯调整与年度报告更正的公告》，对2020年度至2025年第三季度会计期间涉及的部分财务报表及附注数据进行会计差错更正并追溯调整，具体调整事项涉及服务费收入确认不准确、未考虑期后退货对相关年度报表的影响以及调整现金流量表补充资料相关科目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260511/32214760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634426895","title":"股市必读：智飞生物（300122）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634426895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634426895?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:41","pubTimestamp":1778438470,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，智飞生物报收于15.47元，上涨0.59%，换手率1.6%，成交量22.62万手，成交额3.52亿元。2025年度，公司管理层自愿放弃部分2025年度薪酬，总薪酬同比下降。董秘： 您好，2025年度，公司业绩显著承压，公司深刻总结经验教训，着力化解各项经营风险。谢谢董秘： 您好，截至2026年4月30日，公司普通股股东人数为119,480，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","LU2148510915.USD","BK0046","LU2580892862.HKD","BK0077","LU1064130708.USD","300122","LU2580892789.USD","LU1064131003.USD","LU1328615791.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634460934","title":"投资“100万只剩几万块”！智飞生物业绩会上遭吐槽，公司去年巨亏147亿，年报开篇向投资人致歉","url":"https://stock-news.laohu8.com/highlight/detail?id=2634460934","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634460934?lang=zh_cn&edition=full","pubTime":"2026-05-10 12:02","pubTimestamp":1778385720,"startTime":"0","endTime":"0","summary":"智飞生物业绩会上遭吐槽，公司去年巨亏147亿，年报开篇向投资人致歉；重庆首富身家缩水1000亿，高管主动降薪。 对此，公司董事长蒋仁生回应称，对股东的心情深表理解，受行业深度调整等因素影响，公司当前股价持续承压。公司将通过多项举措全力化解风险，同时持续加快产品创新等，逐步推动公司经营企稳向好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-10/doc-inhxktni2914619.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-10/doc-inhxktni2914619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1328615791.USD","BK0188","LU1064131003.USD","300122","LU2580892862.HKD","LU1064130708.USD","BK0046","BK0077","BK0239","LU2148510915.USD","LU2580892789.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781427198200,"stockEarnings":[{"period":"1week","weight":-0.0064},{"period":"1month","weight":-0.2077},{"period":"3month","weight":-0.2361},{"period":"6month","weight":-0.3619},{"period":"1year","weight":-0.3754},{"period":"ytd","weight":-0.345}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"114160人(较上一季度减少0.80%)","perCapita":"12388股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}